| |
|
|
 
Robert M. Wasserman, Director of Research
Mr. Wasserman has over twenty years experience in equity research,
specializing in the area of health care with a unique focus on companies
in the Southeastern US and Florida . Among the areas Mr. Wasserman has covered
are pharmaceuticals, medical devices, healthcare services and biotechnology.
Mr. Wasserman has analyzed and written on over 100 publicly traded health care companies.
Mr. Wasserman was the founder of the Research effort at Dawson James, and he has also served
as Director of Research for Jesup & Lamont, Senior Research Analyst for Craig-Hallum Capital Group and
Vice President-Research and Partner for Southeast Research Partners/Ryan Beck. Prior to entering the securities
industry, Mr. Wasserman was a management consultant with Peat, Marwick, Mitchell & Co., now KPMG Peat Marwick.
Mr. Wasserman was selected All-Star Healthcare analyst for 2000 by the Wall Street Journal,
and has appeared in a number of media outlets, including Business Week, Forbes, The New York Times and CNBC.
Mr. Wasserman received his Masters of Business Administration degree in Finance from the University of Chicago and
dual Bachelor of Science degrees in Management and Engineering from the Massachusetts Institute of Technology.
Vernon T. Bernardino, Senior Research Analyst
Vernon Bernardino brings to Dawson James almost 10 years of experience in investment research specializing in healthcare.
Prior to joining Dawson James, Mr. Bernardino was a senior biotechnology analyst at Rodman & Renshaw, where he provided primary
equity research coverage or support for more than 30 small cap companies. Mr. Bernardino also served as an equity analyst at UBS
covering small and large cap biotechnology companies; and as a healthcare industry analyst at Sturdivant & Co. covering healthcare
companies in the Mid-Atlantic region. He also excelled as a buyside global healthcare research analyst at Nicholas Applegate
Capital Management and as an investment banking analyst with The Camelot Group.
Mr. Bernardino also brings with him biopharmaceutical industry experience as a scientist at Corvas International (acquired by
Dendreon), Schering-Plough (acquired by Merck & Co.) and the University of Medicine and Dentistry of New Jersey. He has participated
in numerous drug discovery research projects in some of today's leading therapeutic targets in cardiovascular disease and AIDS.
Mr. Bernardino received a Masters in Business Administration from the University of San Diego concentrating in Finance, and
received a Bachelor of Arts degree from Rutgers University, where he graduated with Honors.
|
|
